Jill O'Donnell-Tormey
Showing 1–2 of 2 transcripts.
- Milken Institute56 min
Preserving the Promise of Cancer Immunotherapy
Louise Perkins, Pablo Legorreta, Johanna Mercier, Jill O'Donnell-Tormey, Antoni Ribas, Greg Simon
The Melanoma Research Alliance, alongside the Biden Cancer Initiative and L'Oréal Paris, is addressing the persistent 50% non-response rate to current immunotherapies by promoting platform trials and data-sharing networks to eliminate redundant "Me Too" drug development. While recent clinical advances have extended survival for metastatic patients to a decade or more, experts emphasize the urgent need to de-risk academic discoveries through nonprofit incubators and standardized liquid biopsies to prevent early-stage cancer from progressing to terminal stages. Strategic recommendations from industry leaders and researchers prioritize patient-centric trial design and sustained basic science funding to ensure these breakthroughs reach community oncologists and avoid investment withdrawal from other critical therapeutic classes.
- Goldman Sachs9 min
Revolutionizing Cancer Treatment with Immunotherapy: Talks at GS Session Highlights
Giovanni Caforio, Laurie Glimcher, Jill O'Donnell-Tormey, Dr. Giovanni Coforio, Dr. Lori Glimcher, Jamie
Immunotherapy has emerged as a transformative cancer treatment by harnessing the patient's immune system to target mutated cells through checkpoint blockade, offering a personalized alternative to the non-specific toxicity of traditional chemotherapy. Clinical trials in melanoma and lung cancer have demonstrated that this approach yields response rates exceeding 60% and has nearly eliminated the need for first-line chemotherapy in these malignancies. Looking ahead, the field aims to expand these outcomes by addressing patient non-responsiveness through strategies that personalize therapy based on unique tumor genetic profiles.